Literature DB >> 20486940

Multiple sequence variations in SLC5A1 gene are associated with glucose-galactose malabsorption in a large cohort of Old Order Amish.

B Xin1, H Wang.   

Abstract

Glucose-galactose malabsorption (GGM) is an autosomal recessive disease with life-threatening newborn diarrhea caused by mutations in the Na(+) /glucose cotransporter gene SLC5A1. Because of its rarity, the clinical course of the disease has not been well studied. Here, we report 33 patients with GGM from a large Old Order Amish pedigree and the associated mutations in SLC5A1 gene. Clinically, all affected individuals presented with classic watery diarrhea and dehydration. The increased bowel sounds, distended abdomen, vigorous nursing regardless of their illness, and irritability and apathy were also noted as part of the initial presentation. Patients underwent a dramatic turnaround with an immediate cease of the diarrhea and a quick rehydration if they were correctly diagnosed and adequately managed, followed by a normal growth and development pattern afterwards; whereas a prolonged clinical course would follow if the disease was not recognized. Sequence analysis of the 15 protein-coding exons and the corresponding exon-intron boundaries of SLC5A1 gene revealed four homozygous missense mutations, c.152A>G (p.N51S), c.1231G>A (p.A411T), c.1673G>A (p.R558H), and c.1845C>G (p.H615Q), that co-segregate with the GGM phenotype in all of the affected individuals. These findings suggest that founder effect of the SLC5A1 mutations associated with the disease in Amish and a population specific genetic testing is in need to pursue an early diagnosis which is critical for a favorable outcome.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20486940     DOI: 10.1111/j.1399-0004.2010.01440.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  13 in total

Review 1.  Recent progress in congenital diarrheal disorders.

Authors:  Roberto Berni Canani; Gianluca Terrin
Journal:  Curr Gastroenterol Rep       Date:  2011-06

2.  Five-month-old male with chronic diarrhea.

Authors:  Hailey C Barootes; Erin R Peebles; Dhandapani Ashok; Suzanne Ratko; Andrea C Yu
Journal:  Paediatr Child Health       Date:  2019-11-30       Impact factor: 2.253

Review 3.  Relevance of solute carrier family 5 transporter defects to inherited and acquired human disease.

Authors:  Miryam Cannizzaro; Jana Jarošová; Boel De Paepe
Journal:  J Appl Genet       Date:  2019-07-08       Impact factor: 3.240

4.  A novel SGLT is expressed in the human kidney.

Authors:  Rajendra K Kothinti; Amy B Blodgett; Paula E North; Richard J Roman; Niloofar M Tabatabai
Journal:  Eur J Pharmacol       Date:  2012-07-03       Impact factor: 4.432

5.  SLC gene mutations and pediatric neurological disorders: diverse clinical phenotypes in a Saudi Arabian population.

Authors:  Ali Mir; Montaha Almudhry; Fouad Alghamdi; Raidah Albaradie; Mona Ibrahim; Fatimah Aldurayhim; Abdullah Alhedaithy; Mushari Alamr; Maryam Bawazir; Sahar Mohammad; Salma Abdelhay; Shahid Bashir; Yousef Housawi
Journal:  Hum Genet       Date:  2021-11-19       Impact factor: 4.132

6.  Long-Term Dietary Changes in Subjects with Glucose Galactose Malabsorption Secondary to Biallelic Mutations of SLC5A1.

Authors:  Alvin P Chan; Shweta S Namjoshi; Patricia M Jardack; Lisa Maloney; Atrin Ardjmand; Nicholas N Jackson; Martin G Martin
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

Review 7.  Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies.

Authors:  Roberto Berni Canani; Giuseppe Castaldo; Rosa Bacchetta; Martín G Martín; Olivier Goulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 73.082

8.  Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.

Authors:  Arthur T Sands; Brian P Zambrowicz; Julio Rosenstock; Pablo Lapuerta; Bruce W Bode; Satish K Garg; John B Buse; Phillip Banks; Rubina Heptulla; Marc Rendell; William T Cefalu; Paul Strumph
Journal:  Diabetes Care       Date:  2015-06-06       Impact factor: 19.112

Review 9.  Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.

Authors:  Michael A Nauck
Journal:  Drug Des Devel Ther       Date:  2014-09-11       Impact factor: 4.162

10.  Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.

Authors:  Julio Rosenstock; William T Cefalu; Pablo Lapuerta; Brian Zambrowicz; Ike Ogbaa; Phillip Banks; Arthur Sands
Journal:  Diabetes Care       Date:  2014-09-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.